Avalo Therapeutics Presents Positive Phase 2 Abdakibart Data in Hidradenitis Suppurativa

Bitget2026/11/05 16:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Avalo Therapeutics plans to initiate Phase 3 testing of abdakibart for moderate-to-severe hidradenitis suppurativa in the first half of 2027.
The Phase 2 LOTUS trial met its primary endpoint, with combined HiSCR75 response of 42.5% versus 25.6% for placebo.
Abdakibart was well tolerated, with no adverse events related to neutropenia, serious infections or opportunistic infections.
Next-generation anti-IL-1β antibody AVTX-010 is expected to advance to an investigational new drug application in the first half of 2027.
A $431.3 million financing supports expected cash runway into 2029, including anticipated Phase 3 topline data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Avalo Therapeutics Presents Positive Phase 2 Abdakibart Data in Hidradenitis Suppurativa

You may also like

Crypto prices